Status:
COMPLETED
PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)
Lead Sponsor:
University of Colorado, Denver
Conditions:
Polycystic Kidney Disease, Adult
Polycystic Kidney, Autosomal Dominant
Eligibility:
All Genders
18-40 years
Brief Summary
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of end-stage kidney disease (ESKD). The disorder is characterized by development and continued growth of multipl...
Eligibility Criteria
Inclusion
- Patients with Autosomal dominant polycystic kidney disease
- Age 18-40 years
- BMI \>= 18.5 and \<30 kg/m2
- Weight \<350 lbs
Exclusion
- Diabetes mellitus, based on previous diagnosis
- Albuminuria (≥30mg/g) or estimated glomerular filtration rate (eGFR) \<75ml/min/1.73m2
- Pregnancy or nursing
- Anemia
- Allergy to shellfish or iodine
- Vaptan therapy (e.g. tolvaptan)
- Uncontrolled hypertension (average ≥140/90 mmHg)
Key Trial Info
Start Date :
November 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 13 2022
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT04407481
Start Date
November 1 2020
End Date
October 13 2022
Last Update
February 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital Colorado
Aurora, Colorado, United States, 80045